Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 39055657 · doi:10.3389/fcvm.2024.1379189
What was done
A systematic review and random-effects meta-analysis following PRISMA guidelines evaluated randomized clinical trials comparing semaglutide to placebo or active controls (other glucose-lowering drugs). The primary outcome was the C-reactive protein (CRP) index, defined as final CRP divided by basal CRP. Subgroup analyses examined route of administration (subcutaneous vs. oral) and diabetes status (with or without type 2 diabetes mellitus).
What was found
Thirteen randomized clinical trials including 26,131 participants were analyzed. Semaglutide significantly reduced the CRP index compared to placebo (SMD -0.56; 95% CI -0.69 to -0.43, I² = 92%) and compared to active controls (SMD -0.45; 95% CI -0.68 to -0.23, I² = 82%). Reductions remained consistent across subcutaneous versus oral formulations and in patients with or without type 2 diabetes.
Why it matters
These findings quantitatively confirm that semaglutide exerts a systemic anti-inflammatory effect, supporting inflammatory reduction as a plausible mechanism for its cardiovascular risk reduction.
Limits
Statistical heterogeneity was very high (I² of 82% to 92%), suggesting substantial variability across included trials. The evaluation of inflammation was limited to CRP index alone, and the abstract does not report clinical cardiovascular endpoints directly linked to the magnitude of CRP change.
Cited by
- supports GLP-1 receptor agonist medications significantly reduce systemic inflammation.